Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Opens First JLABS Site In Europe

Executive Summary

Johnson & Johnson Innovation has opened its first JLABS incubator in Europe, the 10th worldwide, with close links to its pharma R&D unit Janssen.

You may also be interested in...



Cipla Opens Up To Crowd Sourcing Innovation

Cipla has outlined its intent to incubate disruptive ideas in the healthcare space, along the lines of similar initiatives to accelerate innovation from US/European big pharma. It hopes that this "culture" will expand in India.

UCB Spinout Syndesi Brings New Approach To Dementia

Emerging Company Profile: Syndesi Therapeutics, a new biotech built upon research from UCB, aims to develop novel drugs for neurodegenerative conditions like Alzheimer's disease; the company has a stream of big name investors such as J&J Innovation and Novo Holdings.

Femtech Presents Enticing Market Opportunity

A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.

Topics

Related Companies

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel